Key result
SEA0400 selectively inhibits plasmalemmal NCX while CGP-37157 targets mitochondrial NCX in intact cardiomyocytes.
Why the study?
Pharmacological discrimination between plasmalemmal and mitochondrial sodium–calcium exchangers in cardiomyocytes was unclear.
Population
H9c2 cardiomyocytes loaded with Ca(2+)-sensitive fluorescent probes
Comparison
SEA0400 vs CGP-37157 effects on NCX activity
Design
Preclinical experimental study
Authors
Loading...
Supports distinct plasmalemmal and mitochondrial NCX entities; leaves open in vivo cardiac translation.
SEA0400 and CGP-37157 act as selective inhibitors for plasmalemmal and mitochondrial NCX respectively, providing pharmacological evidence that they are distinct molecular entities.
Namekata et al. (2015) studied In vitro cardiomyocyte study. SEA0400 and CGP-37157 vs. Control (absence of inhibitors) was evaluated on Plasmalemmal and mitochondrial NCX activity (measured by cytoplasmic and mitochondrial Ca2+ concentrations). SEA0400 selectively inhibited plasmalemmal NCX, while CGP-37157 selectively inhibited mitochondrial NCX in intact cardiomyocyte-derived H9c2 cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: